<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02698579</url>
  </required_header>
  <id_info>
    <org_study_id>LTF-304</org_study_id>
    <secondary_id>2015-002805-13</secondary_id>
    <nct_id>NCT02698579</nct_id>
  </id_info>
  <brief_title>Long-term Follow-up of Participants With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug Product</brief_title>
  <official_title>Long-term Follow-up of Subjects With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug Product</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>bluebird bio</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>bluebird bio</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, long-term safety and efficacy follow-up study for participants with&#xD;
      cerebral adrenoleukodystrophy (CALD) who have received Lenti-D Drug Product in a parent&#xD;
      clinical study.&#xD;
&#xD;
      After completing a parent clinical study (approximately 2 years), eligible participants will&#xD;
      be followed for an additional 13 years for a total of 15 years post-drug product infusion. No&#xD;
      investigational drug product will be administered in this study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">January 22, 2016</start_date>
  <completion_date type="Anticipated">May 2037</completion_date>
  <primary_completion_date type="Anticipated">May 2037</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Major Functional Disability (MFD)-Free Survival</measure>
    <time_frame>15 years post-drug-product infusion</time_frame>
    <description>The MFDs are loss of communication, cortical blindness, tube feeding, total incontinence, wheelchair dependence, complete loss of voluntary movement.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants who Experience Graft Versus Host Disease (GVHD)</measure>
    <time_frame>15 years post-drug-product infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants who Undergo Subsequent Stem Cell Transplantation (i.e. Second Hematopoietic Stem Cell [HSC] Infusion)</measure>
    <time_frame>15 years post-drug-product infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Drug Product-Related Adverse Events (AEs)</measure>
    <time_frame>15 years post-drug-product infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Serious Adverse Events (SAEs) (Regardless of Relatedness to Drug Product)</measure>
    <time_frame>15 years post-drug-product infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Serious or non-serious Immune-related Adverse Events (AEs) and New or Worsening Hematologic or Neurologic Disorders or Malignancies</measure>
    <time_frame>15 years post-drug-product infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Vector-derived Replication Competent Lentivirus (RCL), Assessed from Archived Samples as Clinically Indicated</measure>
    <time_frame>5 years post-drug-product infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Insertional Oncogenesis</measure>
    <time_frame>15 years post-drug-product infusion</time_frame>
    <description>Insertional oncogenesis including Myelodysplasia, Leukemia, Lymphoma will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Clonal Predominance</measure>
    <time_frame>15 years post-drug-product infusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>15 years post-drug-product infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Neurological Function Score (NFS)</measure>
    <time_frame>15 years post-drug-product infusion</time_frame>
    <description>The NFS is a 25-point score used to evaluate the severity of gross neurologic dysfunction in CALD by scoring 15 symptoms (functional domains) across 6 categories. Listed here are the 15 symptoms followed by their maximal score out of 25 points: a) Hearing / auditory processing problems-1, b) Aphasia / apraxia-1, c) Loss of communication-3, d) Vision impairment /field cut-1, e) Cortical blindness-2, f) Swallowing / other central nervous system (CNS) dysfunctions-2, g) Tube feeding-2, h) Running difficulties / hyperreflexia-1, i) Walking difficulties / spasticity / spastic gait (no assistance)-1, j) Spastic gait (needs assistance)-2, k) Wheelchair dependence-2, l) Complete loss of voluntary movement-3, m) Episodes of incontinence -1, n) Total incontinence-2, o) Nonfebrile seizures-1. A score of &quot;0&quot; denotes absence of clinical signs of cerebral disease. Maximal signs within a domain score the total of all grades within that domain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Gadolinium Enhancement (GdE) Status</measure>
    <time_frame>15 years post-drug-product infusion</time_frame>
    <description>GdE status means participants who will report GdE negative (-) or positive (+).</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Cerebral Adrenoleukodystrophy (CALD)</condition>
  <condition>Adrenoleukodystrophy (ALD)</condition>
  <condition>X-Linked Adrenoleukodystrophy (X-ALD)</condition>
  <arm_group>
    <arm_group_label>Participants treated with Lenti-D</arm_group_label>
    <description>Partcipants who have received Lenti-D Drug Product in a parent clinical study (bluebird bio-sponsored clinical trial) and who meet the eligibility criteria for the study LTF-304.</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Lenti-D</intervention_name>
    <description>Vector copy number (VCN) measurement, safety evaluations, disease-specific assessments, and assessments to monitor for long-term complications of autologous transplant.</description>
    <arm_group_label>Participants treated with Lenti-D</arm_group_label>
    <other_name>elivaldogene autotemcel</other_name>
    <other_name>eli-cel</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants with cerebral adrenoleukodystrophy (CALD) who have received Lenti-D Drug&#xD;
        Product in a parent clinical study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provision of written informed consent for this study by the participant or&#xD;
             participant's parent(s)/ legal guardian(s) and written informed assent by participant,&#xD;
             if applicable&#xD;
&#xD;
          -  Have received Lenti-D Drug Product in a parent clinical study&#xD;
&#xD;
          -  Able to comply with study requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  There are no exclusion criteria for this Study&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Dietz, MD</last_name>
    <role>Study Director</role>
    <affiliation>bluebird bio, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mattel Children's Hospital-UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital/Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medeos SRL</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's and Children's Hospital</name>
      <address>
        <city>North Adelaide</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital das Clínicas da Universidade de São Paulo</name>
      <address>
        <city>São Paulo</city>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Bicêtre</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <state>Cedex</state>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig AöR</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Brazil</country>
    <country>France</country>
    <country>Germany</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Algeria</country>
  </removed_countries>
  <link>
    <url>https://clinicaltrials.gov/ct2/show/NCT01896102?term=ald-102&amp;rank=1</url>
    <description>Related Info</description>
  </link>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 17, 2016</study_first_submitted>
  <study_first_submitted_qc>March 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2016</study_first_posted>
  <last_update_submitted>March 24, 2021</last_update_submitted>
  <last_update_submitted_qc>March 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adrenoleukodystrophy</keyword>
  <keyword>X-linked Adrenoleukodystrophy</keyword>
  <keyword>Hematopoietic Stem Cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenoleukodystrophy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

